AR080934A1 - Procedimiento de preparacion de composiciones farmaceuticas destinadas a la administracion por via oral que comprenden uno o varios principios activos y las composiciones que las comprenden - Google Patents
Procedimiento de preparacion de composiciones farmaceuticas destinadas a la administracion por via oral que comprenden uno o varios principios activos y las composiciones que las comprendenInfo
- Publication number
- AR080934A1 AR080934A1 ARP110101364A ARP110101364A AR080934A1 AR 080934 A1 AR080934 A1 AR 080934A1 AR P110101364 A ARP110101364 A AR P110101364A AR P110101364 A ARP110101364 A AR P110101364A AR 080934 A1 AR080934 A1 AR 080934A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- composition
- coated granule
- binder
- relation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Procedimiento de recubrimiento en caliente denominado ½ Hot melt coating de principios activos farmacéuticos caracterizados por propiedades organolépticos o fisicoquímicas que son deseables enmascarar. Principios activos medicamentosos con propiedades organolépticas o fisicoquímicas enmascaradas así obtenidas y a las composiciones que los comprenden. Reivindicacion 1: Procedimiento de preparacion de una composicion de principio activo medicamentoso que comprende (a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y (b) una capa de recubrimiento de dicho centro granulado constituida por matriz grasa, composicion en la que: ò el principio activo representa como mínimo 10%, de preferencia 20% o incluso 30% en peso con relacion al peso de la composicion del gránulo recubierto; el principio activo representa como máximo 48%, de preferencia como máximo 40%, de preferencia el principio activo representa de 20% a menos de 40% con relacion al peso de la composicion del gránulo recubierto, más preferentemente el principio activo representa de 30% a 40% con relacion al peso de la composicion del gránulo recubierto; ò la matriz grasa representa más de 50% y hasta 85% en peso de la composicion del gránulo recubierto de preferencia de 51% a 65%, la matriz grasa que comprende opcionalmente un adyuvante, de preferencia se elige entre los agentes hidrofilos, los agentes tensioactivos o sus mezclas, y representando estos ultimos menos de 10%, de preferencia de 1 a 3% en peso con relacion al peso de la composicion del gránulo recubierto; ò el aglomerante, de preferencia un agente hidrofilo elegido entre les polímeros hidrofilos o los agentes termofusibles, representa de 0,2 a 18% en peso con relacion al peso de la composicion del gránulo recubierto, de preferencia el aglomerante representa menos de 18% en peso para un agente termofusible o incluso de preferencia el aglomerante representa menos de 10% en peso para un polímero hidrofilo; ò el diluyente, si es necesario, como agente de carga representa un contenido de 0 a 39% con relacion al peso de la composicion del gránulo recubierto; ò el lubricante, si es necesario, como agente de flujo representa un contenido de 0 a 1,8% con relacion al peso de la composicion del gránulo recubierto; el procedimiento comprende las etapas de: E1) preparacion del centro granulado por pulverizacion de una disolucion acuosa que comprende el aglomerante o por pulverizacion del aglomerante en fusion sobre el principio activo solo o mezclado con un diluyente y/o un lubricante; E2) recubrimiento por pulverizacion sobre los gránulos de dicha matriz grasa previamente fundida en un fusor a una temperatura de alrededor de 10 a 20°C superior a su punto de fusion; E3) enfriamiento de la composicion obtenida. Reivindicacion 16: Procedimiento segun una de las reivindicaciones 1 a 15 en el que el principio activo se elige entre el grupo constituido por antibioticos tales como cefalosporinas y macrolidos, ventajosamente se elige entre: pristinamicina, cefpodoxima, roxitromicina, espiramicina, rovamicina, levofloxacina o el grupo constituido por corticoides tales como prednisolona, metilprednisolona, o también el grupo constituido por AINS tales como ácido tiaprofénico, cetoprofeno, lisinato de cetoprofeno, ibuprofeno, o el grupo constituido por analgésicos como paracetamol, o también el grupo constituido por zopiclona, riluzol, zolpidem, clobazam, tiocolchicosico, hidrocloruro o base de drotaverina, hidrocloruro de amodiaquina, diltiazem, levocetirizina, mizolastina, dronedarona, celivarona, dramamina, ramiprilo, irbesartan, clopidogrel, leflunomida, nicorandil, acetil salicilato de lisina, ramiprilo, citrato de magnesio, levotiroxina, valproato de sodio, rifampicina, artesunato y omeprazol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1053034A FR2959130A1 (fr) | 2010-04-21 | 2010-04-21 | Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080934A1 true AR080934A1 (es) | 2012-05-16 |
Family
ID=42797556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101364A AR080934A1 (es) | 2010-04-21 | 2011-04-20 | Procedimiento de preparacion de composiciones farmaceuticas destinadas a la administracion por via oral que comprenden uno o varios principios activos y las composiciones que las comprenden |
| ARP110101365A AR081539A1 (es) | 2010-04-21 | 2011-04-20 | Composicion a base de fexofenadina y procedimiento de preparacion, sobre o comprimido, uso de la composicion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101365A AR081539A1 (es) | 2010-04-21 | 2011-04-20 | Composicion a base de fexofenadina y procedimiento de preparacion, sobre o comprimido, uso de la composicion |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20130251794A1 (es) |
| EP (2) | EP2560612B1 (es) |
| JP (2) | JP2013525341A (es) |
| KR (2) | KR20130094716A (es) |
| CN (2) | CN102946857A (es) |
| AR (2) | AR080934A1 (es) |
| AU (2) | AU2011262319A1 (es) |
| BR (2) | BR112012026596A2 (es) |
| CA (2) | CA2796816A1 (es) |
| CL (2) | CL2012002898A1 (es) |
| CO (2) | CO6620042A2 (es) |
| EA (2) | EA201291088A1 (es) |
| ES (2) | ES2525163T3 (es) |
| FR (1) | FR2959130A1 (es) |
| IL (2) | IL222578A0 (es) |
| MA (2) | MA34226B1 (es) |
| MX (1) | MX2012012275A (es) |
| PL (2) | PL2560613T3 (es) |
| SG (3) | SG184951A1 (es) |
| TW (2) | TWI478713B (es) |
| UY (2) | UY33350A (es) |
| WO (2) | WO2011151733A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349889B (zh) * | 2011-11-01 | 2013-08-28 | 江苏先声药物研究有限公司 | 一种含有决奈达隆的组合物 |
| JP5841433B2 (ja) * | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
| JP6245677B2 (ja) * | 2012-01-20 | 2017-12-13 | ニプロ株式会社 | 口腔内崩壊錠 |
| JP6255908B2 (ja) * | 2012-11-09 | 2018-01-10 | 大正製薬株式会社 | 固形製剤 |
| FR2999937B1 (fr) * | 2012-12-21 | 2015-01-09 | Sanofi Sa | Unite solide a haute teneur en fexofenadine et son procede de preparation |
| CN104274408A (zh) * | 2013-07-10 | 2015-01-14 | 北京科信必成医药科技发展有限公司 | 一种熔融包衣的速释药物微粒及其制备方法 |
| CN103610645B (zh) * | 2013-11-25 | 2016-05-11 | 浙江万晟药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| WO2016120299A1 (en) * | 2015-01-28 | 2016-08-04 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Orally disintegrating formulations of dronedarone |
| US20180344648A1 (en) * | 2015-11-30 | 2018-12-06 | Piramal Enterprises Limited | Clobazam tablet formulation and process for its preparation |
| EP3363429A1 (en) * | 2017-02-20 | 2018-08-22 | DSM IP Assets B.V. | Process for the production of coated particles |
| EP3670489A1 (en) * | 2018-12-21 | 2020-06-24 | Dompé farmaceutici S.p.A. | Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof |
| JP2023549381A (ja) | 2020-11-18 | 2023-11-24 | バイオファーマ・シナジーズ，エス．エル． | 抗ヒスタミン活性化合物を含む口内分散性粉末組成物 |
| WO2022175829A1 (en) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
| WO2023126637A1 (en) * | 2021-12-29 | 2023-07-06 | Opella Healthcare Group Sas | Compositions containing fexofenadine |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| JPH07100665B2 (ja) * | 1987-12-23 | 1995-11-01 | 信越化学工業株式会社 | 被覆薬剤の製造方法 |
| US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
| DE69129036T2 (de) * | 1990-11-30 | 1998-07-30 | Yamanouchi Pharma Co Ltd | Überdeckte zusammensetzung mit schneller freisetzung |
| US5578322A (en) * | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
| MX9306393A (es) * | 1992-10-16 | 1994-04-29 | Glaxo Group Ltd | Composiciones de ranitidina substancialmente libres de sabor amargo, proceso para su preparacion y composiciones farmaceuticas que las contienen. |
| EP0812195B1 (en) | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| EP0781425A1 (en) * | 1995-06-29 | 1997-07-02 | Eastman Kodak Company | Transfer support and method for fusing a transferable image to a digital disc |
| IT1276160B1 (it) * | 1995-11-22 | 1997-10-27 | Recordati Chem Pharm | Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee |
| FR2753904B1 (fr) * | 1996-10-01 | 1998-10-30 | Gattefosse Ets Sa | Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication |
| US5891476A (en) * | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
| US6274162B1 (en) * | 2000-01-14 | 2001-08-14 | Bpsi Holdings, Inc. | Elegant film coating system |
| FR2811912B1 (fr) * | 2000-07-21 | 2003-02-07 | Gattefosse Ets Sa | Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| FR2838647B1 (fr) * | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
| CN1674874A (zh) * | 2002-08-14 | 2005-09-28 | 纳幕尔杜邦公司 | 涂覆药物颗粒的方法 |
| FR2848855B1 (fr) | 2002-12-23 | 2005-02-11 | Aventis Pharma Sa | Compositions pour administration orale de principes actifs necessitant un masquage du gout |
| DE60308828T2 (de) * | 2003-05-20 | 2007-05-24 | Ethypharm | Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung |
| FR2857263B1 (fr) * | 2003-07-09 | 2005-09-09 | Sanofi Synthelabo | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride |
| WO2005065639A2 (en) * | 2003-11-21 | 2005-07-21 | Torrent Pharmaceuticals Limited | Novel pharmaceutical compositions |
| WO2005062722A2 (en) * | 2003-11-21 | 2005-07-14 | Sun Pharmaceutical Industries Limited | Fexofenadine containing pharmaceutical formulation |
| TR200606412T2 (tr) | 2004-03-19 | 2007-01-22 | Eczaciba�I �Zg�N K�Myasal �R�Nler San. Ve T�C. A �. | Lipit kaplı sefuroksim aksetil hazırlanması |
| US20070048373A1 (en) * | 2005-08-30 | 2007-03-01 | Cima Labs Inc. | Dried milled granulate and methods |
-
2010
- 2010-04-21 FR FR1053034A patent/FR2959130A1/fr not_active Withdrawn
-
2011
- 2011-04-20 AR ARP110101364A patent/AR080934A1/es not_active Application Discontinuation
- 2011-04-20 WO PCT/IB2011/002000 patent/WO2011151733A2/en active Application Filing
- 2011-04-20 MX MX2012012275A patent/MX2012012275A/es not_active Application Discontinuation
- 2011-04-20 PL PL11764289T patent/PL2560613T3/pl unknown
- 2011-04-20 CN CN2011800306473A patent/CN102946857A/zh active Pending
- 2011-04-20 KR KR1020127030328A patent/KR20130094716A/ko not_active Application Discontinuation
- 2011-04-20 SG SG2012077772A patent/SG184951A1/en unknown
- 2011-04-20 EP EP11722553.2A patent/EP2560612B1/en not_active Revoked
- 2011-04-20 ES ES11722553.2T patent/ES2525163T3/es active Active
- 2011-04-20 SG SG2012077764A patent/SG184950A1/en unknown
- 2011-04-20 AU AU2011262319A patent/AU2011262319A1/en not_active Abandoned
- 2011-04-20 KR KR1020127027293A patent/KR20130080428A/ko not_active Application Discontinuation
- 2011-04-20 EA EA201291088A patent/EA201291088A1/ru unknown
- 2011-04-20 ES ES11764289.2T patent/ES2527390T3/es active Active
- 2011-04-20 EP EP11764289.2A patent/EP2560613B1/en not_active Not-in-force
- 2011-04-20 CN CN201180020130.6A patent/CN103002874B/zh not_active Expired - Fee Related
- 2011-04-20 AU AU2011244020A patent/AU2011244020A1/en not_active Abandoned
- 2011-04-20 AR ARP110101365A patent/AR081539A1/es not_active Application Discontinuation
- 2011-04-20 BR BR112012026596A patent/BR112012026596A2/pt not_active IP Right Cessation
- 2011-04-20 CA CA2796816A patent/CA2796816A1/en not_active Abandoned
- 2011-04-20 BR BR112012026938A patent/BR112012026938A2/pt not_active IP Right Cessation
- 2011-04-20 PL PL11722553T patent/PL2560612T3/pl unknown
- 2011-04-20 EA EA201291089A patent/EA201291089A1/ru unknown
- 2011-04-20 SG SG10201506708UA patent/SG10201506708UA/en unknown
- 2011-04-20 WO PCT/IB2011/051736 patent/WO2011132167A1/en active Application Filing
- 2011-04-20 JP JP2013505595A patent/JP2013525341A/ja active Pending
- 2011-04-20 CA CA2796821A patent/CA2796821A1/en not_active Abandoned
- 2011-04-20 MA MA35362A patent/MA34226B1/fr unknown
- 2011-04-20 MA MA35363A patent/MA34227B1/fr unknown
- 2011-04-20 JP JP2013505569A patent/JP2013525340A/ja active Pending
- 2011-04-21 TW TW100113944A patent/TWI478713B/zh not_active IP Right Cessation
- 2011-04-21 TW TW100113943A patent/TW201204415A/zh unknown
- 2011-04-25 UY UY0001033350A patent/UY33350A/es not_active Application Discontinuation
- 2011-04-25 UY UY0001033351A patent/UY33351A/es not_active Application Discontinuation
-
2012
- 2012-10-17 CL CL2012002898A patent/CL2012002898A1/es unknown
- 2012-10-18 CO CO12184708A patent/CO6620042A2/es not_active Application Discontinuation
- 2012-10-18 CL CL2012002909A patent/CL2012002909A1/es unknown
- 2012-10-19 CO CO12185243A patent/CO6620043A2/es not_active Application Discontinuation
- 2012-10-21 IL IL222578A patent/IL222578A0/en unknown
- 2012-10-21 IL IL222576A patent/IL222576A0/en unknown
- 2012-10-22 US US13/657,404 patent/US20130251794A1/en not_active Abandoned
- 2012-10-22 US US13/657,396 patent/US20130183382A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080934A1 (es) | Procedimiento de preparacion de composiciones farmaceuticas destinadas a la administracion por via oral que comprenden uno o varios principios activos y las composiciones que las comprenden | |
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| PE20142442A1 (es) | Formulacion de farmaco de liberacion retardada | |
| HRP20191711T1 (hr) | Oftalmološki pripravak | |
| TWI540132B (zh) | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 | |
| HRP20161138T1 (hr) | Farmaceutski pripravak za oralnu primjenu | |
| AR065039A1 (es) | Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso | |
| JP2011506340A5 (es) | ||
| BR112015025172A2 (pt) | composição farmacêutica | |
| PE20080423A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| KR20110135870A (ko) | 구강내 붕괴성 피복 정제 | |
| RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| AR109981A1 (es) | Formulación liposomal | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| HRP20191412T1 (hr) | Pripravci s kontroliranim oslobađanjem i postupci njihove upotrebe | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| Nevado et al. | Neomycin and bacitracin reduce the intestinal permeability in mice and increase the expression of some tight-junction proteins | |
| AR105203A1 (es) | Formulación oral sólida que contiene irinotecán y método de preparación de la misma | |
| ES2247362T3 (es) | Composiciones farmaceuticas orales con biodisponibilidad mejorada. | |
| JP2013523676A5 (es) | ||
| KR101659983B1 (ko) | 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제 | |
| HRP20161794T1 (hr) | Novi terapijski pristupi za liječenje neuroinflamatornih stanja | |
| WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| AR094770A1 (es) | Composición masticable para administración oral y proceso para preparar la misma | |
| RU2015119243A (ru) | Твердые дисперсии нерастворимого лекарственного средства и способы их приготовления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |